You are here

Article Text

Article menu
Download PDFPDF
Letter
Tocilizumab for multirefractory adult-onset Still’s disease
  1. M De Bandt,
  2. B Saint-Marcoux
  1. Unit of Rheumatology, R Ballanger Hospital, Aulnay sous Bois, France
  1. Dr M De Bandt, Unit of Rheumatology, R Ballanger Hospital, Aulnay sous Bois, 93600, France; m.debandt{at}ch-aulnay.fr

https://doi.org/10.1136/ard.2008.088179

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Adult-onset Still’s disease (AOSD) is a multisystemic inflammatory disease of unknown cause, characterised by daily spiking fever, rash, leucocytosis and arthritis. Cytokines such as interleukin (IL)1, 6 and 18, interferon γ, tumour necrosis factor are thought to have a role in the pathogenesis of the disease.1 2 Treatments such as non-steroidal anti-inflammatory drugs, steroids, methotrexate (MTX), gold, azathioprine, leflunomide, ciclosporin and biological agents (tumour necrosis factor blockers, IL1 receptor antagonist or rituximab) can help in the management of patients, depending on presentation and disease course.3–5

    We report on a young woman with refractory AOSD successfully treated with anti-IL6 receptor antibody (tocilizumab), whose efficacy has been shown in …

    View Full Text

    Footnotes

    • Competing interests: None.

    • Patient consent: Obtained.